Skip to main content
. Author manuscript; available in PMC: 2021 Nov 8.
Published in final edited form as: J Clin Immunol. 2019 May 10;39(3):277–286. doi: 10.1007/s10875-019-00638-z

Table 2 -.

Currently Approved Therapies for CAPS

Anakinra Rilonacept Canakinumab
Pharmacology IL-1 receptor antagonist IL-1 receptor fusion protein IL-1β monoclonal antibody
Half- life ~4–6 hours ~8 days ~26 days
Approved Dosage (Ped) 100 mg (1–8 mg/kg) sq 160–320 mg (2.2–4.4 mg/kg) sq 150 – 300 mg (2–4 mg/kg) sq
Dosage Frequency 1 day 1 week 4–8 weeks
Side Effects Infection, site reaction Infection, site reaction Infection, vertigo
FDA approval (Age) CINCA/NOMID (8 mo) FCAS / MWS (12 yrs) FCAS / MWS (2 yrs)
EMA approval (Age) CAPS (8 mo) CAPS (2 yrs)

Cryopyrin associated periodic syndrome (CAPS), Familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), Chronic infantile neurologic cutaneous articular (CINCA) syndrome or Neonatal onset multisystemic inflammatory disease (NOMID), Pediatric dosing (Ped), age approved for treatment (Age), milligram (mg), kilogram (kg), subcutaneous (sq).